Discovery of a Potent Candidate for RET-Specific Non-Small-Cell Lung Cancer—A Combined In Silico and In Vitro Strategy
Rearranged during transfection (RET) is a tyrosine kinase oncogenic receptor, activated in several cancers including non-small-cell lung cancer (NSCLC). Multiple kinase inhibitors vandetanib and cabozantinib are commonly used in the treatment of RET-positive NSCLC. However, specificity, toxicity, an...
Guardado en:
Autores principales: | Priyanka Ramesh, Woong-Hee Shin, Shanthi Veerappapillai |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a8566ba4770e4e44b5ad36e030ac27ad |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A Rational Design of α-Helix-Shaped Peptides Employing the Hydrogen-Bond Surrogate Approach: A Modulation Strategy for Ras-RasGRF1 Interaction in Neuropsychiatric Disorders
por: Maria Rita Gulotta, et al.
Publicado: (2021) -
A new series of 2,4-thiazolidinediones endowed with potent aldose reductase inhibitory activity
por: Sever Belgin, et al.
Publicado: (2021) -
Editorial: Protein–Protein Interactions: Drug Discovery for the Future
por: Simona Rapposelli, et al.
Publicado: (2021) -
Computer-Aided Discovery of Pentapeptide AEYTR as a Potent Acetylcholinesterase Inhibitor
por: Enade Perdana Istyastono, et al.
Publicado: (2020) -
Discovery is the researcher’s dream
por: Magaly Bascones, et al.
Publicado: (2021)